OnKure Therapeutics Inc (OKUR) Short-Term Debt to Equity

Graphic logo of OnKure Therapeutics Inc (OKUR)

The price action history of OnKure Therapeutics Inc (OKUR) demonstrates metrics at the level of 0.01. OnKure Therapeutics Inc develops advanced tumor therapies, with intellectual property that enables the global scaling of products with high profitability. The brand is recognized as an expert in the targeted treatment of complex pathologies. The business is currently focusing on internal molecular research, having completed the asset consolidation process.

OKUR - OnKure Therapeutics Inc Short-Term Debt to Equity Ratio over the range 10/08/2024 - 11/01/2026

Financial and market metric breakdowns for OnKure (OKUR)

- stock quotes and analyst forecast:
Stock Price OnKure Therapeutics Inc|OKUR - Analyst Consensus Forecast
- market capitalization details:
Market Value OnKure Therapeutics, Inc.|OKUR - Business Value
- balance sheet equity data:
Book Value per Share OnKure Therapeutics|OKUR - Company Net Assets|Market Capitalization to Book Value Ratio onkuretherapeutics.com|OKUR - Company Assets
- business debt structure and liquidity details:
Debt to Equity OnKure Therapeutics Inc|OKUR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio OnKure Therapeutics Inc|OKUR - Aggregate Debt Obligations|Debts to Book Capitalization OnKure Therapeutics, Inc.|OKUR - Company Long-Term Liabilities|Company Current Liabilities OnKure Therapeutics|Quick Liquidity onkuretherapeutics.com
- earnings and market ratios statistics:
OKUR - Final Profit
Fundamental valuation:OnKure Therapeutics
Signature product of onkuretherapeutics.com

Investors are evaluating OnKure Therapeutics Inc (OKUR) through the lens of clinical trial success, where access to capital is critical for continuing research regardless of market cycles. An analysis of the company's short-term leverage history allows for an assessment of the proportion of liabilities maturing within one year relative to equity, signaling liquidity risks or financial stability ahead of a new funding round.

Competitors of OnKure Therapeutics Inc

Short-Term Debt to Capital ONC|Short-Term Debt to Capital Halozyme Corp (HALO)|Short-Term Debt to Equity Revolution Medicines RVMD|AAPG: Short-Term Debt to Capital Ratio|CG Oncology - Short-Term Debt to Capital|UroGen Pharma Ltd (URGN) - Short-Term Debt to Equity Ratio|BCAX: Short-Term Debt to Capital|Current Liabilities to Capital Personalis Genomics (PSNL)|Short-Term Debt to Equity Erasca, Inc.|DCTH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio YMAB (Y-mAbs Therapeutics, Inc.)|AURA (Aura Biosciences Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CADL (Candel Therapeutics, Inc.)|ARAY - Short-Term Debt to Equity Ratio|SLS: Short-Term Debt to Equity Ratio|ACTU - Short-Term Debt to Capital|Citius Oncology (CTOR) - Short-Term Debt to Equity|TuHURA Biosciences - Ratio of Short-Term Indebtedness to Capital|TARA (Protara) - Short-Term Debt to Capital|Current Liabilities to Capital Fate Pharma FATE|Short-Term Debt to Equity Aadi Bioscience Inc (WHWK)|TCRX - Current Liabilities to Capital|Short-Term Debt to Equity Champions Oncology, Inc. CSBR|XBIT: Short-Term Debt to Capital Ratio|CVM - Short-Term Debt to Equity|OSTX - Short-Term Debt to Capital|RADX (Radiopharm Theranostics) - Short-Term Debt to Equity Ratio|Artiva Biotherapeutics (ARTV) - Short-Term Debt to Capital|Short-Term Debt to Equity Adlai Nortye Ltd|VERU: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital TPST|XLO - Current Liabilities to Capital|Renovaro - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital MURA|KAPA: Short-Term Debt to Equity Ratio|CytoMed Therapeutics - Short-Term Loans to Capital Ratio|CRIS: Short-Term Debt to Capital|Apollomics - Ratio of Short-Term Indebtedness to Capital|THAR (Tharimmune, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Advanced Biomed Corp ADVB|Short-Term Debt to Equity Genprex (GNPX)|CLDI (calidibio.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SBFM (Sunshine Biopharma)|Short-Term Debt to Capital Xenetic Biosciences Inc. XBIO|SLRX - Short-Term Debt to Equity|Current Liabilities to Equity PPBT|AONC: Short-Term Debt to Capital|Current Liabilities to Capital BeiGene Ltd. (BGNE)|Short-Term Debt to Equity Ratio CKPT|Short-Term Debt to Capital Elevation Oncology Inc.|Short-Term Debt to Equity Ratio ICAD (iCAD, Inc.)|Short-Term Loans to Capital Ratio IKNA|Short-Term Debt to Capital NTBL (Notable Labs)|Short-Term Debt to Capital Coefficient Viracta Therapeutics Inc. (VIRX)|MorphoSys Corp - Short-Term Debt to Capital|NAYA Biosciences Corp (NAYA) - Short-Term Debt to Equity Ratio|Ascentage Pharma Group (AAPGV) - Short-Term Debt to Equity